retatrutide phase 2 obesity trial results New 3 data just dropped 👀 Eli Lilly's reported average weight loss approaching 30%, with some patients achieving historically associated with bariatric surgery. A few important caveats Retatrutide as a Novel Treatment

Couffinhal, T., Duplaa, C., Moreau, C., Lamaziere, J

Higher average weight loss compared to many older therapies Potential improvements in cardiovascular and liver health Multifactorial action: impacts metabolism, appetite, and fat storage Might help treat related conditions such as sleep apnea and chronic pain Less frequent dosing due to longer half-life Better results may be achieved with retatrutide in the care of a physician, especially for those who have not responded to therapies currently available

Starting weight and metabolic health : Participants with type 2 diabetes lost less weight (-16.9% at 12mg) than those without diabetes (-24.2%)

Upcoming catalyst events the order and 6ming of expected GLP-1 and other clinical outcomes in weight loss/obesity to be announced

We are not a pharmacy, we do not dispense or fulfill prescriptions

Hormone replacement therapy (HRT) and glucagon-like peptide-1 (GLP-1) agonists have traditionally been considered separate therapeutic modalities